| Steven J Ruden Dds Pc | |
|
216 Sea Cliff Ave Sea Cliff NY 11579 | |
| (516) 676-8148 | |
| (516) 676-9029 |
| Full Name | Steven J Ruden Dds Pc |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 216 Sea Cliff Ave, Sea Cliff, New York |
| Authorized Official Name and Position | Steven J Ruden (MANAGER) |
| Authorized Official Contact | 5166768148 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Steven J Ruden Dds Pc Po Box 320 216 Sea Cliff Ave Sea Cliff NY 11579 Ph: (516) 676-8148 | Steven J Ruden Dds Pc 216 Sea Cliff Ave Sea Cliff NY 11579 Ph: (516) 676-8148 |
| NPI Number | 1376513671 |
|---|---|
| Provider Enumeration Date | 01/26/2006 |
| Last Update Date | 07/29/2014 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376513671 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 029140 (New York) | Primary |
News Archive
Depression, known to be a condition with impaired psychosocial functioning that severely impacts the quality of life of patients and families, is actually defined with specific clinical symptoms such as sadness, difficulty to experience pleasure, sleep problems etc., present for at least two weeks. At least 40% of depressed patients actually benefit from an antidepressant treatment, whereas 20-30% of patients may suffer from chronic depression that negatively impacts their quality of life. In order to improve the efficiency of treatment and reduce the burden of depressive disorders, depression needs to be defined at the neurobiological level.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.
OPKO Health, Inc. announced today that it has been awarded a grant from the Dravet Syndrome Foundation to support the Company's efforts to develop potential therapeutic agents to treat a rare genetic disorder, Dravet Syndrome, also called severe myoclonic epilepsy of infancy, a severe form of epilepsy that usually appears during the first year of life.
A comprehensive analysis of previous studies including more than 114,000 subjects has shown that high levels of chocolate consumption are associated with a significant reduction in the risk of certain cardiovascular disorders.
› Verified 2 days ago